fbpx
January 18, 2022

Risankizumab Effective Against Refractory Psoriatic Arthritis Risankizumab Effective Against Refractory Psoriatic Arthritis

NEW YORK (Reuters Health) – Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly […]
January 15, 2022

FDA Approves Two Oral JAK Inhibitors for Atopic Dermatitis FDA Approves Two Oral JAK Inhibitors for Atopic Dermatitis

The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them […]
January 15, 2022

FDA Updates Status of iPLEDGE Access Problems FDA Updates Status of iPLEDGE Access Problems

The Isotretinoin Products Manufacturers Group (IPMG) reports that most users of the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) should now have access to their accounts, one month after […]
January 12, 2022

Sorting Out Sleep Complaints in Children With AD Can Be Complex Sorting Out Sleep Complaints in Children With AD Can Be Complex

An estimated 50% of children with atopic dermatitis (AD) struggle with sleep problems, with complaints that vary from sleep fragmentation to restlessness and limb movements, according […]
January 7, 2022

Ask These Key Questions About Atopic Dermatitis Sleep Problems Ask These Key Questions About Atopic Dermatitis Sleep Problems

If you don’t think it’s important to assess for sleep disorders in your patients with atopic dermatitis (AD), think again. According to Sabra M. Abbott, MD, PhD, […]
January 6, 2022

Atopic Dermatitis’ Longitudinal Course Often Gets Overlooked Atopic Dermatitis’ Longitudinal Course Often Gets Overlooked

In the opinion of Raj Chovatiya, MD, PhD, the longitudinal course of atopic dermatitis (AD) is an important yet overlooked clinical domain of the disease. Dr […]
January 5, 2022

Itch-Dominant Atopic Dermatitis Often Flies Under the Radar Itch-Dominant Atopic Dermatitis Often Flies Under the Radar

In the clinical experience of Jonathan I. Silverberg, MD, PhD, MPH, atopic dermatitis (AD) patients with severe itch and mild to moderate lesions often fall through […]
January 4, 2022

Atopic Dermatitis Can Be Especially Burdensome in the Elderly Atopic Dermatitis Can Be Especially Burdensome in the Elderly

Atopic dermatitis (AD) may be especially active and severe among older adults, and it may be associated with increased risk of comorbid conditions common in later […]
December 30, 2021

FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis

The Food and Drug Administration has accepted a new drug application (NDA) for roflumilast, a topical phosphodiesterase type 4 (PDE4) inhibitor for treating psoriasis in adults and […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0